{"entity":{"id":"chongqing-precision-biotech","kind":"company","name":"Chongqing Precision Biotech","aka":["Chongqing Precision Biotech Co., Ltd"],"tldr":"Chongqing Precision Biotech is a China-based cell therapy company running 2 late-stage cancer trials in multiple myeloma.","summary":"Chongqing Precision Biotech, based in Chongqing, China, is a cell therapy company. Precision Biotech is a Chinese biopharmaceutical company focused on cell-based drug development, specialising in CAR-T cell immunotherapies including a marketed paediatric/adolescent leukaemia CAR-T product. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in multiple myeloma. The largest, NCT04271644 (BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease), plans to enrol 80 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.precision-biotech.com"},{"label":"ClinicalTrials.gov: trials led by Chongqing Precision Biotech","url":"https://clinicaltrials.gov/search?lead=Chongqing%20Precision%20Biotech%20Co.%2C%20Ltd"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["multiple-myeloma"],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct04271644","nct05334823","nct04776330"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Chongqing","country":"CN","companyType":"cell-therapy","website":"https://www.precision-biotech.com","stage":"growth","investors":[],"funding":[]},"route":"/companies/chongqing-precision-biotech/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}],"trial":[{"id":"nct04776330","kind":"trial","name":"a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","route":"/trials/nct04776330/"},{"id":"nct05334823","kind":"trial","name":"A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents","route":"/trials/nct05334823/"},{"id":"nct04271644","kind":"trial","name":"BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","route":"/trials/nct04271644/"}]}}